Literature DB >> 24846220

Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells.

Sheena Pinto1, Daniel Sommermeyer, Chloé Michel, Susanne Wilde, Dolores Schendel, Wolfgang Uckert, Thomas Blankenstein, Bruno Kyewski.   

Abstract

Immunity to tumor differentiation antigens, such as melanoma antigen recognized by T cells 1 (MART-1), has been comprehensively studied. Intriguingly, CD8(+) T cells specific for the MART-1(26(27)-35) epitope in the context of HLA-A0201 are about 100 times more abundant compared with T cells specific for other tumor-associated antigens. Moreover, MART-1-specific CD8(+) T cells show a highly biased usage of the Vα-region gene TRAV12-2. Here, we provide independent support for this notion, by showing that the combinatorial pairing of different TCRα- and TCRβ- chains derived from HLA-A2-MART-1(26-35) -specific CD8(+) T-cell clones is unusually permissive in conferring MART-1 specificity, provided the CDR1α TRAV12-2 region is used. Whether TCR bias alone accounts for the unusual abundance of HLA-A2-MART-1(26-35) -specific CD8(+) T cells has remained conjectural. Here, we provide an alternative explanation: misinitiated transcription of the MART-1 gene resulting in truncated mRNA isoforms leads to lack of promiscuous transcription of the MART-1(26-35) epitope in human medullary thymic epithelial cells and, consequently, evasion of central self-tolerance toward this epitope. Thus, biased TCR usage and leaky central tolerance might act in an independent and additive manner to confer high frequency of MART-1(26-35) -specific CD8(+) T cells.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Central tolerance; Human medullary thymic epithelial cells; MART-1; Melanoma; Promiscuous gene expression

Mesh:

Substances:

Year:  2014        PMID: 24846220     DOI: 10.1002/eji.201444499

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

1.  Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.

Authors:  Stefanie Gross; Michael Erdmann; Ina Haendle; Steve Voland; Thomas Berger; Erwin Schultz; Erwin Strasser; Peter Dankerl; Rolf Janka; Stefan Schliep; Lucie Heinzerling; Karl Sotlar; Pierre Coulie; Gerold Schuler; Beatrice Schuler-Thurner
Journal:  JCI Insight       Date:  2017-04-20

2.  Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors.

Authors:  Slobodan Culina; Ana Ines Lalanne; Georgia Afonso; Karen Cerosaletti; Sheena Pinto; Guido Sebastiani; Klaudia Kuranda; Laura Nigi; Anne Eugster; Thomas Østerbye; Alicia Maugein; James E McLaren; Kristin Ladell; Etienne Larger; Jean-Paul Beressi; Anna Lissina; Victor Appay; Howard W Davidson; Søren Buus; David A Price; Matthias Kuhn; Ezio Bonifacio; Manuela Battaglia; Sophie Caillat-Zucman; Francesco Dotta; Raphael Scharfmann; Bruno Kyewski; Roberto Mallone
Journal:  Sci Immunol       Date:  2018-02-02

3.  TCR-ligand dissociation rate is a robust and stable biomarker of CD8+ T cell potency.

Authors:  Mathilde Allard; Barbara Couturaud; Laura Carretero-Iglesia; Minh Ngoc Duong; Julien Schmidt; Gwennaëlle C Monnot; Pedro Romero; Daniel E Speiser; Michael Hebeisen; Nathalie Rufer
Journal:  JCI Insight       Date:  2017-07-20

Review 4.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

5.  Priming of Qualitatively Superior Human Effector CD8+ T Cells Using TLR8 Ligand Combined with FLT3 Ligand.

Authors:  Anna Lissina; Olivia Briceño; Georgia Afonso; Martin Larsen; Emma Gostick; David A Price; Roberto Mallone; Victor Appay
Journal:  J Immunol       Date:  2015-11-25       Impact factor: 5.422

6.  Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.

Authors:  Chantal Saberian; Rodabe N Amaria; Amer M Najjar; Laszlo G Radvanyi; Cara L Haymaker; Marie-Andrée Forget; Roland L Bassett; Silvana C Faria; Isabella C Glitza; Enrique Alvarez; Sapna Parshottam; Victor Prieto; Gregory Lizée; Michael K Wong; Jennifer L McQuade; Adi Diab; Cassian Yee; Hussein A Tawbi; Sapna Patel; Elizabeth J Shpall; Michael A Davies; Patrick Hwu; Chantale Bernatchez
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

7.  Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.

Authors:  Sabine Schmied; Emma Gostick; David A Price; Hinrich Abken; Mario Assenmacher; Anne Richter
Journal:  Immunology       Date:  2015-06-19       Impact factor: 7.397

8.  Broadening the repertoire of melanoma-associated T-cell epitopes.

Authors:  Thomas Mørch Frøsig; Rikke Lyngaa; Özcan Met; Stine Kiær Larsen; Marco Donia; Inge Marie Svane; Per Thor Straten; Sine Reker Hadrup
Journal:  Cancer Immunol Immunother       Date:  2015-02-18       Impact factor: 6.968

9.  Naive CD8⁺ T-cell precursors display structured TCR repertoires and composite antigen-driven selection dynamics.

Authors:  Michelle A Neller; Kristin Ladell; James E McLaren; Katherine K Matthews; Emma Gostick; Johanne M Pentier; Garry Dolton; Andrea J A Schauenburg; Dan Koning; Ana Isabel C A Fontaine Costa; Thomas S Watkins; Vanessa Venturi; Corey Smith; Rajiv Khanna; Kelly Miners; Mathew Clement; Linda Wooldridge; David K Cole; Debbie van Baarle; Andrew K Sewell; Scott R Burrows; David A Price; John J Miles
Journal:  Immunol Cell Biol       Date:  2015-03-24       Impact factor: 5.126

10.  Reduced naïve CD8(+) T-cell priming efficacy in elderly adults.

Authors:  Olivia Briceño; Anna Lissina; Kerstin Wanke; Georgia Afonso; Amrei von Braun; Kristanto Ragon; Tiphaine Miquel; Emma Gostick; Laura Papagno; Karin Stiasny; David A Price; Roberto Mallone; Delphine Sauce; Urs Karrer; Victor Appay
Journal:  Aging Cell       Date:  2015-10-15       Impact factor: 9.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.